|
Re: OTC short number increses by 40+k in first half of November
|
1
|
Resverlogix Corp.
|
Nov 26, 2021 02:18AM
|
|
Re: Our own BKC on the webcast
|
3
|
Resverlogix Corp.
|
Feb 06, 2021 01:28PM
|
|
Re: Our own BKC on the webcast
|
5
|
Resverlogix Corp.
|
Feb 04, 2021 01:04PM
|
|
Re: Our own BKC on the webcast
|
6
|
Resverlogix Corp.
|
Feb 04, 2021 02:43PM
|
|
Re: Patience
|
1
|
Resverlogix Corp.
|
Jun 20, 2021 08:54AM
|
|
Re: Patience
|
2
|
Resverlogix Corp.
|
Jan 18, 2022 09:40AM
|
|
Re: Per MD&A - Liquidity same old- no cash waiting on PP or pship
|
|
Resverlogix Corp.
|
Dec 15, 2020 02:56PM
|
|
Re: Please keep post respectful
|
6
|
Resverlogix Corp.
|
Jan 23, 2021 07:59AM
|
|
Re: Please keep post respectful
|
2
|
Resverlogix Corp.
|
Jan 23, 2021 03:47PM
|
|
Re: Presentation is gone
|
2
|
Resverlogix Corp.
|
May 14, 2021 10:01AM
|
|
Re: Presentation is gone
|
2
|
Resverlogix Corp.
|
May 14, 2021 02:54PM
|
|
Re: Price
|
3
|
Resverlogix Corp.
|
Dec 31, 2020 11:23AM
|
|
Re: Quote from a January 19, 2021 review
|
1
|
Resverlogix Corp.
|
Jan 21, 2021 04:45PM
|
|
Re: Rant time...
|
|
Resverlogix Corp.
|
Feb 05, 2021 11:35AM
|
|
Re: Rant time...
|
|
Resverlogix Corp.
|
Feb 05, 2021 12:43PM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
|
Resverlogix Corp.
|
Dec 22, 2020 05:42PM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
2
|
Resverlogix Corp.
|
Dec 22, 2020 08:02AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
5
|
Resverlogix Corp.
|
Dec 22, 2020 08:13AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
4
|
Resverlogix Corp.
|
Dec 22, 2020 08:59AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
1
|
Resverlogix Corp.
|
Dec 22, 2020 11:10AM
|
